T2 Biosystems Announces Amendment and Extension of CRG Term Loan Agreement
10 nov. 2022 16h04 HE
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the...
T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
09 nov. 2022 16h05 HE
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced...
HHS and the Cohen Foundation Name T2 Biosystems a Phase 1 Winner in LymeX Diagnostics Prize
07 nov. 2022 08h30 HE
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today...
T2 Biosystems Regains Compliance with Nasdaq’s Minimum Bid Price Rule
01 nov. 2022 08h30 HE
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...
T2 Biosystems to Report Third Quarter 2022 Financial Results on November 10, 2022
31 oct. 2022 17h57 HE
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today...
T2 Biosystems Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel
20 oct. 2022 09h05 HE
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today...
T2 Biosystems Highlights Multiple New Studies Demonstrating Improved Rapid Detection Across Several Patient Populations
14 oct. 2022 08h30 HE
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Oct. 14, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today...
T2 Biosystems Announces Plan to Commercialize a Diagnostic Test for Early Lyme Disease
13 oct. 2022 09h00 HE
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today...
T2 Biosystems Announces Preliminary Third Quarter 2022 Financial Results and Updates 2022 Financial Outlook
12 oct. 2022 08h35 HE
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...
T2 Biosystems Announces Reverse Stock Split Effective Today
12 oct. 2022 08h30 HE
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...